Company Overview
Snapshot
Founded in July 2018 by David Yizhar, Raviv Itzhaky, and Ofer Barnea, Geneyx Genomex operates with 11–50 employees. The company has raised $14 million across 8 funding rounds from 4 investors. In March 2024, Children's Mercy Kansas City and Geneyx Inc. announced a collaboration to advance genomic research and analysis.
Business overview
Geneyx Genomex provides an AI-based genetic data analysis platform focused on integrating comprehensive genomic insights into healthcare and pharmaceutical research. The company's core product, Geneyx Analysis, offers secondary and tertiary analysis of germline and somatic sequencing data interpretation, designed to improve diagnostic yields and turnaround times. Geneyx serves a diverse client base including hospitals, genetics labs, and life-science companies, operating within the digital healthcare, digital medical diagnostics, and medical decision support sectors.
Strategic signal
In September 2024, Geneyx was selected for Google's new Google for Startups Accelerator: AI First program. This participation signals strong validation of Geneyx's AI capabilities and strategic importance in the health tech sector, providing access to Google Cloud and Google DeepMind expertise, mentorship, and resources to accelerate its growth and impact in AI-driven genomic analysis.
Log in to access full profile ›Company Intelligence Q&A
- What was a significant partnership for Geneyx Genomex in early 2024?
- In March 2024, Children's Mercy Kansas City and Geneyx Inc. announced a collaboration to advance genomic research and analysis, utilizing Geneyx Analysis for long-read sequencing data interpretation in pediatric healthcare.
- Which accelerator program did Geneyx Genomex join in 2024?
- In September 2024, Geneyx Genomex was selected as one of three Israeli startups to join the Google for Startups Accelerator: AI First program, developed in partnership with Google Cloud.
- What was a key strategic partnership for Geneyx Genomex in May 2023?
- In May 2023, Mediclinic Middle East partnered with Geneyx and Digi7 to implement an AI-based solution for next-generation sequencing data, aiming to accelerate genetic diagnosis and research in the Middle East.
- When did Geneyx Genomex raise its seed funding round and who were the lead investors?
- In November 2021, Geneyx Genomex raised a seed round with lead investors.
- What acquisition did Geneyx Genomex make in October 2020?
- In October 2020, Geneyx Genomex acquired Toldot Genetics from BATM Advanced Communications and minority shareholders, integrating Toldot's next-generation sequencing analysis technology into its platform.